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Summary
Effective control and monitoring of foot-and-mouth disease (FMD) relies upon rapid
and accurate disease confirmation. Currently, clinical samples are usually tested in
reference laboratories using standardized assays recommended by The World
Organisation for Animal Health (OIE). However, the requirements for prompt and
serotype-specific diagnosis during FMD outbreaks, and the need to establish robust
laboratory testing capacity in FMD-endemic countries have motivated the develop-
ment of simple diagnostic platforms to support local decision-making. Using a porta-
ble thermocycler, the T-CORTM 8, this study describes the laboratory and field
evaluation of a commercially available, lyophilized pan-serotype-specific real-time
RT-PCR (rRT-PCR) assay and a newly available FMD virus (FMDV) typing assay
(East Africa-specific for serotypes: O, A, Southern African Territories [SAT] 1 and 2).
Analytical sensitivity, diagnostic sensitivity and specificity of the pan-serotype-speci-
fic lyophilized assay were comparable to that of an OIE-recommended laboratory-
based rRT-PCR (determined using a panel of 57 FMDV-positive samples and six
non-FMDV vesicular disease samples for differential diagnosis). The FMDV-typing
assay was able to correctly identify the serotype of 33/36 FMDV-positive samples
(no cross-reactivity between serotypes was evident). Furthermore, the assays were
able to accurately detect and type FMDV RNA in multiple sample types, including
epithelial tissue suspensions, serum, oesophageal–pharyngeal (OP) fluid and oral
swabs, both with and without the use of nucleic acid extraction. When deployed in
laboratory and field settings in Tanzania, Kenya and Ethiopia, both assays reliably
detected and serotyped FMDV RNA in samples (n = 144) collected from pre-clinical,
clinical and clinically recovered cattle. These data support the use of field-ready
rRT-PCR platforms in endemic settings for simple, highly sensitive and rapid detec-
tion and/or characterization of FMDV.
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1 | INTRODUCTION
Early detection of foot-and-mouth disease virus (FMDV), a highly
infectious picornavirus, is essential to minimize the impacts of foot-
and-mouth disease (FMD) in susceptible populations. FMD is ende-
mic in many countries throughout Africa, Asia and parts of South
America, existing as seven distinct FMDV serotypes (A, O, C, Asia 1,
Southern African Territories [SAT] 1, 2 and 3), which are distributed
unevenly worldwide within seven geographically defined pools
(Paton, Sumption, & Charleston, 2009). Laboratory-based diagnostic
tests play an essential role in FMD control and eradication by pro-
viding accurate confirmation of clinical signs. Real-time reverse-tran-
scription polymerase chain reaction (rRT-PCR) has been widely
adopted by FMD reference laboratories as a principal tool for FMDV
detection, offering high analytical sensitivity and rapid sample
throughput (Reid et al., 2009; Shaw et al., 2007). Pan-serotype-spe-
cific rRT-PCR assays, targeting conserved regions of the FMDV RNA
genome (Callahan et al., 2002; Reid et al., 2002), were used during
the UK 2007 FMDV outbreak to test 99.1% of 3,246 diagnostic
samples submitted to the UK National Reference Laboratory for
FMD (The Pirbright Institute, UK) (Reid et al., 2009).
Although laboratory-based tests provide rapid and accurate
results, sample transportation to the laboratory can negatively affect
the quality of the specimens (if shipped incorrectly) and delay/or
even hinder the processes of immediate critical decision-making and
disease control. Furthermore, many diagnostic procedures require
sophisticated and expensive equipment, limiting their application in
low- and middle-income countries (LMICs), which lack the infrastruc-
ture and financial resources for veterinary diagnostics and surveil-
lance of endemic diseases such as FMD (Namatovu et al., 2013;
Paton et al., 2009; Vosloo, Bastos, Sangare, Hargreaves, & Thomson,
2002). The control of FMD has been recognized by the Food and
Agricultural Organization of the United Nations (FAO) and The
World Organisation for Animal Health (OIE) as a global priority
(Sumption, Domenech, & Ferrari, 2012). However, with effective
control strategies requiring knowledge of FMD distribution and epi-
demiology, the deployment of simple point-of-care test (POCT) plat-
forms for active FMDV detection, monitoring and characterization
remains an ongoing research effort.
The compatibility of an OIE-recommended rRT-PCR assay with
POCT platforms has already been demonstrated (Hearps, Zhang, &
Alexandersen, 2002; Madi et al., 2012; Monwina, Clavijo, Li, Col-
lignon, & Kitching, 2007; Paix~ao et al., 2008). For instance, portable
rRT-PCR has been deployed in field settings for accurate detection
of FMDV in serum, epithelial suspensions and oesophageal–pharyn-
geal fluid (OP) fluid (Howson et al., 2015). However, current assay
formats and platforms are currently limited by low sample
throughput, the requirement for RNA extraction (and thus methods
and equipment to perform this) or are commercially unavailable. Fur-
thermore, evaluation of POCT rRT-PCR platforms has only been per-
formed using FMDV pan-serotype-specific assay formats. With
methods of FMD control in endemic settings relying upon rapid and
accurate identification of the particular FMDV serotype circulating in
the field (e.g. targeted vaccination) (Sumption et al., 2012), there have
been efforts to design serotype-specific assays (tailored to the region)
that target variable capsid-coding regions of the FMDV genome
(Ahmed et al., 2012; Bachanek-Bankowska et al., 2016; Giridharan,
Hemadri, Tosh, Sanyal, & Bandyopadhyay, 2005; Jamal & Belsham,
2015; Knowles et al., 2016; Reid et al., 2014). The transfer of these
FMDV-typing rRT-PCR assays onto POCT platforms could further
strengthen the diagnostic capacity of LMIC laboratories by offering a
simple solution for rapid and improved FMDV characterization.
This study evaluates the performance of a commercially available
lyophilized FMDV pan-serotype-specific rRT-PCR assay
(TC-9092-064; Tetracore, Inc., MD, USA), and a newly available East
Africa-specific typing assay (Bachanek-Bankowska et al., 2016), both
performed on the T-CORTM 8 (Tetracore, Inc.), a portable, battery-
powered thermocycler (Almassian, Cockrell, & Nelson, 2013). The
assessment was performed within laboratory and East African field
settings, providing an approach that can type FMDV in situ using
molecular methods.
2 | MATERIALS AND METHODS
Laboratory work was carried out at The Pirbright Institute (UK),
the Foot-and-Mouth Disease Laboratory (Embakasi, Kenya) and
Sokoine University of Agriculture (SUA) (Morogoro, Tanzania). Field
work was carried out in FMD-endemic settings: Morogoro Region
(Tanzania), Nakuru and Kericho County (Kenya) and Adama (Ethio-
pia) (Figure 1). These sites were selected on the basis of existing
collaborations with investigators working on the epidemiology of
FMD.
2.1 | Ethics
Clinical samples used in this study for laboratory evaluation were
archival samples generated in previous in vivo studies approved by
The Pirbright Institute ethical review committee under the Animal
Scientific Procedures Act (ASPA) and clinical field samples previously
submitted to the World Reference Laboratory for FMD (WRLFMD;
The Pirbright Institute, UK).
Field sampling in Tanzania was conducted as part of an ongoing
research project under the Wellcome Trust Intermediate Fellowship
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FMD (WT104017MA, awarded to CJK), which aligned with the stan-
dards set in ASPA guidelines. Sampling in Kenya was carried out as
part of a training programme run by The European Commission for
the Control of Foot-and-Mouth Disease (EuFMD), and in Ethiopia,
field sampling was carried out as part of an OIE twinning project
“Strengthening the capacity of foot-and-mouth diagnosis and surveil-
lance in Ethiopia and East Africa”.
2.2 | Viruses and clinical samples for laboratory
evaluation
2.2.1 | Sensitivity and specificity of lyophilized
pan-serotype-specific rRT-PCR reagents
Analytical sensitivity (limit of detection [LOD]) was determined using
FMDV RNA extracted from decimal dilution series (101 to 108) of
cell culture isolates O/TAN/39/2012 (topotype East Africa-2); A/
TAN/6/2013 (topotype AFRICA, lineage G-I); SAT 1/KEN/72/2010
(topotype I [North West Zimbabwe]); SAT 2/KEN/2/2008 (topotype
IV) diluted in negative bovine epithelial suspensions (10% [w/v] in
M25 phosphate buffer: 35 mM Na2HPO4 , 5.7 mM KH2PO4, pH
7.6). RNA extraction was performed using the MagMAXTM-96 Viral
RNA Isolation Kit (Applied Biosystems, Thermo Fisher Scientific,
MA, USA) following an automated nucleic acid extraction procedure
on a KingFisherTM Flex (Thermo Fisher Scientific).
Diagnostic sensitivity was assessed using RNA extracted from a
panel of 57 clinical samples (previously submitted to the WRLFMD),
representing five serotypes (O, A, SAT 1, SAT 2 and Asia 1) from ten
countries (Appendix S1). Diagnostic specificity was determined using
RNA extracted from original epithelial suspensions from the follow-
ing vesicular disease viruses: swine vesicular disease virus (UKG/24/
1972; UKG/50/1972; UKG/51/1972; UKG/68/1972), vesicular
stomatitis Indiana virus (VSIND1V) and vesicular stomatitis New Jer-
sey virus (VSNJV).
The diagnostic window for detection (time points post-infection
when FMDV can be detected within clinical samples) was deter-
mined using RNA extracted from archival samples obtained from
unvaccinated intradermolingual needle inoculated cattle, challenged
with FMDV isolate A/TAI/17/2016 (topotype ASIA, lineage Sea-97).
Samples comprised of serum (n = 11) and mouth swabs (n = 11)
taken daily from two animals from the day of challenge and epithe-
lium (n = 4) and OP fluid (n = 2) collected from the same animals
post-mortem (carried out on the day of culling).
2.2.2 | Initial laboratory analysis of the lyophilized
East Africa typing rRT-PCR reagents
Initial laboratory analysis of the East Africa-specific typing assay was
performed on RNA extracted from 36 samples (serotypes O, A, SAT 1
and SAT 2) originating from East Africa (samples from Tanzania and
Kenya included in Appendix S1). These samples were characterized by
the WRLFMD using an antigen-detection ELISA (Ferris & Dawson,
1988) and sequencing of the VP1 region (Knowles et al., 2016), as sta-
ted in the guidelines of the diagnostic manuals of the OIE (OIE, 2012).
2.2.3 | Determination of simple sample preparation
protocols
Optimization of field-ready protocols for the simple preparation of
clinical samples prior to rRT-PCR was carried out by preparing deci-
mal dilution series (101 to 109) of FMDV isolate O/UAE/2/2003
(topotype Middle East-South Asia, lineage Irn-2001) in three sepa-
rate diluents: negative bovine epithelium suspension, negative bovine
serum and negative bovine OP fluid obtained from either archival
experimental studies, or a UK abattoir post-mortem. Aliquots were
stored at 80°C until use. Nine sample preparation procedures were
evaluated, based on their applicability to field settings (Table 1). The
MagMAXTM-96 Viral RNA Isolation Kit/KingFisherTM Flex was used as
the reference sample preparation procedure. Direct detection proto-
cols were then tested on the unvaccinated needle inoculated cattle
samples, described above.
2.3 | Clinical samples for field evaluation
Samples (n = 144) from 78 individual cattle at 13 farms across East
Africa were analysed in situ. Samples were collected opportunistically
from locations where a local animal health worker or farmer reported
the presence of clinical signs consistent with FMDV infection. This
comprised of 13 cattle from two small holdings in Kericho County
(Kenya, June 2016), 16 cattle from two small holdings in Nakuru
County (Kenya, June 2016), 43 cattle from seven small holdings in
Morogoro Rural and Mvomero Districts (Morogoro Region, Tanzania,
September 2016) and six cattle from two small holdings in Adama
(Ethiopia, October, 2016) (Figure 1). Samples were collected from
F IGURE 1 Field locations in East Africa. The bottom right map
depicts the location of the antigenically defined foot-and-mouth
disease virus pools within Africa (Paton et al., 2009). Field sampling
locations are representative of foot-and-mouth disease virus pool 4
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cattle at different stages of infection (acute, convalescent and recov-
ered) and included one or more of the following sample types per
animal: serum, lesion swab, OP fluid and mouth/foot epithelium
(Appendix S2). Cattle from the same herds that had no history or clin-
ical signs of FMD at the time of the visit were also sampled (n = 12).
2.4 | Sample preparation for field evaluation
Loose epithelial tissue of ruptured vesicular lesions from either the
mouth or feet was prepared using the SVANODIP FMDV-Ag
Extraction Kit and SVANODIP FMDV-Ag LFD Kit (Boehringer
Ingelheim) as previously described (Howson et al., 2015). Epithelial
samples from the feet (inter-digital space/coronary band) were
briefly washed in nuclease free water (NFW) prior to processing to
remove soil contaminants. The homogenate was left to settle for
1 min, and then, the supernatant was removed and diluted one in
10 in NFW prior to analysis.
Swabs (GenoTube Livestock, Thermo Fisher Scientific) were col-
lected by swabbing the surface of ruptured lesions in the mouth or
on the feet (inter-digital space/coronary band). The feet were
cleaned in sterile water prior to swabbing in order to remove soil
contaminants. Swabs were then agitated by hand in 1 ml NFW,
which was used directly in analysis.
OP fluid was collected using a suitably sized probang cup follow-
ing the guidelines within the diagnostic manuals of the OIE (2012)
and diluted one in 10 in NFW prior to analysis.
Blood (10 ml) was collected from either the jugular or tail vein
using Vacutainer Plus Plastic Serum Tubes (BD, Plymouth, UK), or
similar. Samples were then transported back to the local laboratory
and centrifuged at 3,000 g for 10 min. Serum was removed and then
diluted one in 10 in NFW prior to analysis.
2.5 | Real-time RT-PCR (rRT-PCR)
2.5.1 | Laboratory-based rRT-PCR
An OIE-recommended pan-serotype-specific one-step rRT-PCR was
used as the reference assay. Each sample was tested in duplicate,
using primers and probes reported by Callahan et al. (2002) and
reagents, parameters and thermal cycling conditions as per Shaw
et al. (2007). Positive reactions were defined as those which gave a
detectable CT.
At The Pirbright Institute, rRT-PCR was performed on a bench
top real-time PCR machine (Stratagene Mx3005p: Agilent Technolo-
gies, CA, USA) using nucleic acid extracted with the MagMAXTM-96
Viral RNA Isolation Kit and KingFisherTM Flex robot (as above). In East
African laboratories, RNA was extracted using the QIAamp Viral
RNA Mini Kit (Qiagen, UK) and rRT-PCR reactions performed on
either a PikoRealTM Real-Time PCR System (Thermo Fisher Scientific)
(Foot-and-Mouth Disease Laboratory, Kenya) or Applied Biosystems
7500 fast thermal cycler (Applied Biosystems) (SUA, Tanzania).
2.5.2 | rRT-PCR using the T-CORTM 8
The FMDV lyophilized pan-serotype-specific assay was performed in
duplicate using FMDV 2.0 reagents with inhibition control (TC-
9092-064, Tetracore Inc.). This assay contains proprietary primers
and probes to target two areas within the highly conserved 3D
TABLE 1 Details of sample preparation methods
Method Procedure
MagMaxTM
(reference)
RNA was extracted using the MagMAXTM - 96 Viral RNA Isolation Kit according to manufacturer guidelines (50 ll sample:
130 ll of lysis/binding solution, eluted in 90 ll; manual 1836M, revision H [Applied Biosystems]) using a KingFisherTM
Flex robot (Thermo Fisher Scientific)
MagMaxTM
(manual)
RNA was extracted as above using a DynaMagTM- Spin magnet (Thermo Fisher Scientific). To meet biosecurity procedures the
sample was added to lysis buffer before the magnetic beads
QIAamp QIAamp Viral RNA Mini Kit (Qiagen, UK) was used according to manufacturer’s guidelines. RNA was extracted from 140 ll
of sample (using the spin column protocol) and eluted in a final volume of 60 ll
1 in 5 dilution Samples diluted 1 in 5 in NFW
1 in 10 dilution Samples diluted 1 in 10 in NFW
1 in 20 dilution Samples diluted 1 in 20 in NFW
Filter Samples were diluted 1 in 5 in NFW and 1 ml of sample passed through an Acrodisc 25 mm syringe filter (w/0.1 lm
Supor Membrane) (Pall Life Sciences, MI, USA)
Chelex 100 50 ll of 50% (w/v) Chelex 100 (Bio-Rad, CA, USA) was added to 500 ll of pre-diluted sample (1 in 5). Samples were
vortexed, allowed to settle and the supernatant used in assays
Chelex (heat) Samples were heated at 56°C for 10 min prior to processing with Chelex 100 as above
Ag-LFDa 200 ll of sample was added to SVANODIP FMDV-Ag LFDs (Boehringer Ingelheim, Bracknell, UK) and incubated at room temperature
(25°C) for 72 hr. Nucleic acid was extracted from the loading pad and wicking strip of the Ag-LFDs as previously published
(Fowler et al., 2014)
NFW, nuclease free water; Ag-LFD, antigen-detection lateral flow device; FMDV, foot-and-mouth disease virus.
aEpithelium only.
Methods used for determination of simple sample preparation protocols in the laboratory.
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region of the FMDV genome (probes labelled with 6-fluorescein ami-
dite [FAM]), in addition to an exogenous internal control with corre-
sponding primers and probes (probe labelled with Cy 5). The East
Africa-specific typing rRT-PCR used the same chemistry, with the
primers and probes as previously published in Bachanek-Bankowska
et al. (2016). In the typing assay, probes for each serotype were
modified for multiplex detection using the following fluorescence
channels: O (Dragonfly OrangeTM), A (FAM), SAT 1 (Cy5) and SAT 2
(Texas Red). Positive reactions were defined as those which gave a
detectable CT.
To each reaction, 20 ll of resuspension buffer and 5 ll of sample
were added. Reactions were performed on a T-CORTM 8 (Tetracore,
Inc.) with the following cycling conditions: 48°C for 15 min, 95°C for
2 min, followed by 45 cycles of 95°C for 10 s and 60°C for 40 s.
2.6 | Biosafety procedures in the field
During field work, a biosafety boundary was established outside of
each farm premises, to separate livestock-containing areas (consid-
ered contaminated) from livestock-free areas (considered uncontami-
nated). This was established to ensure that field work did not
contribute to the further spread of FMDV. Sample preparation and
assay assembly was performed inside the contaminated area. Assem-
bled reactions (rRT-PCR master mix plus sample) were surface disin-
fected with either citric acid (0.2% w/v) or FAM 30 (1:240) prior to
transfer to the uncontaminated area where rRT-PCR on the T-CORTM
8 was performed. Different personnel were present in these areas
to facilitate the transfer of samples. Personnel entering the contami-
nated area donned disposable over-suits, two pairs of gloves and
over-shoes which were surface disinfected as above prior to disposal
within a bag (along with disposable consumables) for incineration at
local laboratory facilities. Any non-disposable equipment which was
used in the contaminated area (e.g., probang cup, forceps, scissors
and boots) was suitably surface disinfected prior to transfer back to
the uncontaminated area. Following each test and between farms,
the T-CORTM 8 was surface disinfected (as above) and sprayed with
DNAZapTM PCR DNA Degradation Solutions (Thermo Fisher Scien-
tific). At the end of field work, the T-CORTM 8 and non-disposable
equipment were surface disinfected (as above) prior to fumigation
with formaldehyde (10 mg/m3) at 30°C (relative humidity > 70 for >
60 min). Samples for concordance testing were added to Mag-
MAXTM-96 Viral RNA lysis buffer within the contaminated area, sur-
face disinfected (as above) for transfer to the uncontaminated area
and transported (double-contained) to appropriate local laboratory
facilities on ice.
2.7 | Statistical analysis
Cohen’s Kappa statistic (j) and the proportion of observed agree-
ment (Aobs) were used to measure the agreement between diagnostic
tests. Statistical analyses were performed using R (R Core Team,
2014).
F IGURE 2 Limit of detection analysis
for lyophilized pan-serotype-specific
reagents compared to the reference real-
time reverse transcription PCR (rRT-PCR)
across four different serotypes (O/TAN/
39/2012; A/TAN/6/2013; Southern
African Territories [SAT] 1/KEN/72/2010;
SAT 2/KEN/2/2008). (●) reference rRT-
PCR performed on a benchtop
thermocycler; (○) pan-serotype-specific
lyophilized reagents performed on the T-
CORTM 8. Points represent the mean of
two replicates; crossed points indicate that
of the identical replicates, one was positive
and the other negative. The error bars
indicate the range
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3 | RESULTS
3.1 | Sensitivity and specificity of lyophilized
pan-serotype-specific rRT-PCR reagents
The analytical sensitivity of the lyophilized pan-serotype-specific
reagents, performed on the T-CORTM 8, was equivalent to the refer-
ence rRT-PCR across the four serotypes tested (both consistently
detected down to 106 for each serotype) (Figure 2). Diagnostic sen-
sitivity of the pan-serotype-specific lyophilized assay was 100%
across the 57 FMDV-positive samples tested (Appendix S1), with all
diagnostic samples tested displaying comparable CT values to the ref-
erence rRT-PCR (Figure 3a). The specificity of the pan-serotype-spe-
cific lyophilized assay was also 100% (n = 6), in that no cross-
reactivity was observed with the other vesicular disease viruses
tested (Appendix S1). FMDV RNA was detected in serum from 1–
4 days post-challenge, mouth swabs from 2 days onwards post-chal-
lenge and all epithelium and OP samples collected post-mortem
using the lyophilized pan-serotype-specific reagents (Figure 4).
3.2 | Initial laboratory analysis of the lyophilized
East Africa-specific typing rRT-PCR reagents
For the East African clinical samples tested in the laboratory
(n = 36), the serotype-specific typing assay detected 7/8 serotype A,
9/10 serotype O, 7/7 serotype SAT 1 and 10/11 serotype SAT 2
(Appendix S1 and Figure 3b). The three samples for which no sero-
type was detected generated high CT values on the reference rRT-
PCR (values of 35.64, 27.18 and 30.65). No cross-reactivity among
serotypes was observed for any of the clinical samples tested.
F IGURE 4 Determination of clinical detection window for the
pan-serotype-specific lyophilized real-time reverse transcription PCR
reagents. Assays performed on extracted RNA on the T-CORTM 8
included the following sample types: (●) serum; (■) mouth swabs;
(▲) foot epithelium; (▼) mouth epithelium; (♦) oesophageal–
pharyngeal (OP) fluid. Assays performed directly (one in 10 dilution)
on samples using the T-CORTM 8 included the following sample
types: (○) serum; (□) mouth swabs; (M) foot epithelium; (▽) mouth
epithelium; (♢) OP fluid. Points represent the mean of two replicates
and crossed points represent when one replicate was positive and
the other negative
F IGURE 3 Comparison between lyophilized pan-serotype-specific reagents and reference real-time reverse transcription PCR. (a) Pan-
serotype-specific rRT-PCR compared to the reference rRT-PCR across a panel of 57 foot-and-mouth disease virus (FMDV)-positive clinical
samples. (b) Serotype-specific rRT-PCR compared to the reference rRT-PCR across a panel of 36 FMDV-positive clinical samples from East
Africa. The colour of points indicates serotype: blue (A), red (O), yellow (Southern African Territories [SAT] 1) and purple (SAT 2). For both
graphs, points represent the mean of two replicates
6 | HOWSON ET AL.
3.3 | Determination of simple sample preparation
protocols
The use of simple extraction kits (QIAmp and MagMaxTM [manual])
achieved similar analytical sensitivity across all three sample types
tested in comparison with the reference sample preparation proce-
dure (MagMaxTM extraction) for both the reference rRT-PCR and lyo-
philized rRT-PCR (Figure 5). Simple sample preparation protocols of
epithelial material resulted in complete inhibition of the reference
rRT-PCR (Figure 5). However, when these same sample preparations
were tested with the lyophilized rRT-PCR reagents (e.g., dilution in
NFW and the use of a filter), a log10 reduction in analytical sensitiv-
ity compared with the use of extracted RNA. Alternative methods,
such as the use of use of Chelex 100 or elution from Ag-LFDs, did
not increase analytical sensitivity for either rRT-PCR assay (Figure 5).
Although serum could be added directly to both the reference
rRT-PCR and lyophilized rRT-PCR, the analytical sensitivity was
higher with the lyophilized rRT-PCR. For all other methods tested,
the analytical sensitivity for the two rRT-PCR assays was similar,
with dilution in NFW and/or the use of Chelex 100 or a syringe fil-
ter required to improve the LOD (Figure 5). For OP fluid, a log10
reduction (relative to MagMaxTM extraction) was evident for both
rRT-PCR reagents when diluted one in 10 in NFW prior to analysis.
The additional use of syringe filters, Chelex 100 or other dilutions
resulted in a further decrease in LOD (Figure 5).
Dilutions of one in 10 of un-extracted clinical samples (animal
study samples) enabled FMDV RNA to be detected in 26/28 FMDV-
positive samples (defined using the reference rRT-PCR with
extracted RNA) using the lyophilized pan-serotype-specific rRT-PCR
(Figure 4), comparatively to 19/28 for the reference rRT-PCR (data
not shown). The two discordant samples (false-negatives) for the lyo-
philized pan-serotype-specific rRT-PCR had CT values of 35.3 (serum
4 days post-challenge) and 29.0 (OP fluid taken post-mortem) when
using extracted RNA.
3.4 | Detection of FMDV in situ using lyophilized
rRT-PCR in East Africa
The T-CORTM 8 and the newly developed rRT-PCR protocols were
tested on 144 samples from 78 cattle across 13 farms in East Africa.
Using the pan-serotype-specific lyophilized rRT-PCR in combina-
tion with the T-CORTM 8, FMDV RNA was identified in 5/5
F IGURE 5 Comparison of sample
preparation methods for the reference
real-time reverse transcription PCR (rRT-
PCR) and lyophilized pan-serotype-specific
rRT-PCR. Sample preparation methods
were tested for three sample types
(epithelial suspensions, sera and
oesophageal–pharyngeal [OP] fluid) across
a dilution series (101 to 109). Elution
from antigen-detection lateral-flow devices
(Ag-LFD) was tested for epithelial
suspensions only:  represent Ag-LFD
results. Black squares represent dilutions
where both replicates were positive for
FMDV; grey squares represent dilutions
where one replicate was positive; white
squares represent reactions where both
replicates were negative for FMDV. For
the reference rRT-PCR, the use of simple
sample preparation methods for epithelium
resulted in assay inhibition in known
positive samples (bar the use of Ag-LFD)
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epithelial, 1/1 swab and 3/3 sera samples collected from cattle dis-
playing 1- to 3-day-old lesions. FMDV RNA was identified in 13/14
epithelial, 15/19 swab, 3/4 OP fluid and 3/29 sera samples collected
from cattle displaying 4- to 7-day-old lesions. Of the 27 cattle that
displayed lesions older than 1 week (8+ days post-initial lesion pre-
sentation), FMDV RNA was identified in 3/12 OP fluid samples,
whilst all sera (n = 25) and swab (n = 10) samples were negative.
FMDV was not detected in any OP fluid (n = 8), mouth swab (n = 2)
or sera (n = 12) sample collected from the 12 clinically negative cat-
tle (Figure 6) (Appendix S2).
Samples considered positive by the lyophilized pan-serotype-spe-
cific assay (n = 46), in addition to a selection of samples from cattle
considered clinically negative (n = 7), were then subsequently char-
acterized using the East Africa-specific typing assay which has been
developed to detect all known FMDV strains relevant to this region
(Bachanek-Bankowska et al., 2016). Of these, 24 were identified as
F IGURE 6 In situ real-time reverse transcription PCR (rRT-PCR) results for 144 East African samples using lyophilized rRT-PCR reagents
and the T-CORTM 8. Samples were collected from cattle displaying clinical signs of foot-and-mouth disease and cattle with no clinical signs
(NCS). Each point represents an average for a single sample (tested in duplicate) on the pan-serotype-specific rRT-PCR (samples that share the
same CT will only appear as a single point with individual CT values presented within supplementary data); crossed points indicate that out of
the duplicates, one was positive and the other negative. Positive samples were then tested using the typing assay; the colour of the points
represents the serotype detected: blue (serotype A), red (serotype O) and white (serotype not detected). The 22/46 FMDV-positive samples
where the serotype was not detected had pan-serotype-specific CT values of > 29 (using lyophilized reagents)
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either A or O (Figure 6); no amplification was present for samples
collected from clinically FMD-negative cattle. FMDV-positive sam-
ples where the serotype was not detected (n = 22) had pan-sero-
type-specific CT values of > 29 (using lyophilized reagents)
(Appendix S2).
For comparison, 99 of the samples tested on the pan-serotype-
specific lyophilized rRT-PCR (using the T-CORTM 8) were also tested
using the reference rRT-PCR within local laboratory settings in East
Africa. High agreement was apparent (j = 0.864, p = 2.109e-15,
Aobs = 0.936) between pan-serotype-specific assays in terms of posi-
tive and negative test results (Figure 7), with all discordant results
between tests having CT values of >36 (Appendix S2), which is at
the threshold of the analytical sensitivity of both tests.
4 | DISCUSSION
The requirement for rapid diagnosis of FMD has led to an increase
in the development and evaluation of POCT for FMDV detection. In
addition to providing a means to rapidly confirm cases of FMD on or
close to the farm during outbreaks, these technologies could poten-
tially provide a route for LMICs to establish robust field/laboratory
testing capacity. For example, immunological-based assays such as
lateral-flow devices (Ag-LFDs) have been developed for rapid viral
antigen detection and successfully tested in situ during the UK 2007
FMDV outbreak (Ryan et al., 2008). However, Ag-LFDs have only
been validated for use with epithelial suspension and vesicular fluid,
and limited analytical sensitivity restricts their usefulness to the
acute stage of infection (Ferris et al., 2009, 2010). As a
consequence, attempts to transfer highly sensitive rRT-PCR assays
onto portable detection platforms have been investigated (Hearps
et al., 2002; Howson et al., 2015; Madi et al., 2012; Monwina et al.,
2007; Paix~ao et al., 2008), but are either not commercially available
or are only suitable for research purposes (i.e., not diagnostic use).
This study evaluates the performance of a commercially available,
lyophilized FMDV pan-serotype-specific assay, in combination with a
commercially available portable thermocycler, in laboratory and East
African field settings. Such tests have the potential to contribute
valuable epidemiological information to support country-level and
regional control programmes, such as the Progressive Control Path-
way for FMD (Sumption et al., 2012). The future success and imple-
mentation of such technologies depends upon several factors,
including dissemination of information and adoption of these
methodologies into current diagnostic strategies.
The provision of reagents in a lyophilized kit format simplifies
reagent storage by negating the requirement for a cold chain, whilst
minimizing the requirement for skilled personnel and multiple pipet-
ting stages by streamlining assay set up (assays only require addition
of a resuspension buffer and sample). The lyophilized pan-serotype-
specific reagents, in combination with the T-CORTM 8, maintained
comparable diagnostic performance to the reference rRT-PCR when
evaluated with extracted RNA. A one to two log10 reduction in ana-
lytical sensitivity for the lyophilized pan-serotype-specific reagents
was evident when no extraction method was used; however, perfor-
mance was still equivalent to the sensitivity of the reference rRT-
PCR when a diagnostic cut-off of CT <32 (as recommended by Shaw
et al., 2007) was applied to the reference rRT-PCR. As the lyophi-
lized pan-serotype-specific reagents are still able to perform rRT-
PCR in the absence of extraction, they offer a potential solution for
molecular POCT in field settings, which is not possible using the ref-
erence rRT-PCR.
Throughout field validation of the T-CORTM 8 in East Africa, lyo-
philized reagents generated results consistent with clinical observa-
tions, with FMDV detected in samples from the early onset of
infection through to delayed viral clearance. Results were gained in
less than 1.5 hr from sample collection. High concordance was evi-
dent between results gained in the field (T-CORTM 8 rRT-PCR) and
local East African laboratories (reference rRT-PCR), with any dis-
agreements associated with samples that had CT values above the
diagnostic threshold of CT < 32 (Shaw et al., 2007). Although the
provision of simple FMDV-positive/negative results is sufficient for
the confirmation of FMD during outbreaks, the value of this infor-
mation is limited in countries where FMD is endemic. In these situa-
tions, it is beneficial to characterize circulating FMDV outbreaks in
order to make tailored control programmes a realistic possibility
(Namatovu et al., 2013). In support of this, this study also evaluated
a lyophilized version of a published FMDV-typing assay specific to
East Africa (Bachanek-Bankowska et al., 2016). The typing assay was
able to characterize FMDV present in four different sample types
collected from seven small holdings (three in Kenya, three in Tanza-
nia and one in Ethiopia) where cattle were presenting two to seven-
day-old FMD lesions. Samples which were unable to be typed
F IGURE 7 Comparison between real-time reverse transcription
PCR (rRT-PCR) results performed using lyophilised pan-serotype
specific rRT-PCR in the field and reference rRT-PCR performed in
local laboratories
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(n = 22) were all considered as weak positives by the lyophilized
pan-serotype-specific rRT-PCR (CT > 29) and therefore at the
threshold at which characterization information can be routinely
obtained by sequencing. The typing assay performance in field set-
tings is therefore consistent with the ability to obtain characteriza-
tion data within laboratory settings. Two serotypes were detected
during the period of testing (O and A), leading to the first reported
characterization of FMDV at the pen-side using molecular methods.
In conclusion, this publication describes the laboratory and field
evaluation of lyophilized FMDV-specific rRT-PCR assays in combina-
tion with a portable thermocycler. The simplicity of the T-CORTM 8
to operate, combined with robust lyophilized reagents, high sensitiv-
ity and compatibility with simple sample preparation methods,
demonstrates an important transition for FMDV-specific rRT-PCR
assays into formats suitable for use on or close to the point-of-care.
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